Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial
Adding GEM to CDDP did not improve 2-year DFS in MIBC patients treated with TMT. Results should be interpreted cautiously due to early study termination and insufficient accrual.
Authors
- Nicolas Demogeot
- Nazim Khalladi
- Thomas Simon (ORCID: https://orcid.org/0000-0001-9699-959X)
- Magali Quivrin
- C. Durdux
- Thomas Reynaud (ORCID: https://orcid.org/0000-0002-4376-0697)
- D. Azria (ORCID: https://orcid.org/0000-0002-7533-2988)
- Morgan Michalet (ORCID: https://orcid.org/0000-0002-6302-825X)
- C. Llacer-Moscardo (ORCID: https://orcid.org/0000-0002-7773-5481)
- M. Charissoux
- O. Riou
- Philippe Ronchin
- D. Tosi
- Naji Salem
- Stéphane Culine
- Sophie Gourgou
- Jean-Michel Hannoun-Lévi
Institutions
- Inserm (FR)
- Université de Montpellier (FR)
- Centre Georges François Leclerc (FR)
- Institut de Cancérologie de Lorraine (FR)
- Centre François Baclesse (LU)
- Hôpital Européen (FR)
- Centre François Baclesse (FR)
- Centre Azuréen de Cancérologie (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Hôpital Saint-Louis (FR)
- Institut Paoli-Calmettes (FR)
- Centre Antoine Lacassagne (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1016/j.radonc.2026.111443
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00